Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus
- 7 December 2006
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 152 (6), 1051.e1-1051.e8
- https://doi.org/10.1016/j.ahj.2006.07.029
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Peroxisome Proliferator–Activated Receptor-γ Activation With Pioglitazone Improves Endothelium-Dependent Dilation in Nondiabetic Patients With Major Cardiovascular Risk FactorsCirculation, 2006
- Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory BiomarkersArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individualsEuropean Heart Journal, 2004
- Cardiovascular Therapies and Risk for Development of DiabetesJournal of the American College of Cardiology, 2004
- C-Reactive Protein Attenuates Endothelial Progenitor Cell Survival, Differentiation, and FunctionCirculation, 2004
- Rosiglitazone Facilitates Angiogenic Progenitor Cell Differentiation Toward Endothelial LineageCirculation, 2004
- Troglitazone Stimulates Repair of the Endothelium and Inhibits Neointimal Formation in Denuded Rat AortaArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Glitazones and Heart FailureCirculation, 2003
- PPARγ and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosisThe Lancet, 1992